Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.61    0.01 (0.63%)
Bid:
1.61
Ask:
2.00
Spread: 0.39 (24.224%)
Market Cap: £5.65m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

New Registered Address

12 Jun 2017 07:00

RNS Number : 6479H
Proteome Sciences PLC
12 June 2017
 

 

 

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company"

 

 

New Registered Address

 

 

 

Proteome Sciences plc (AIM:PRM) is pleased to announce that its corporate headquarters have moved from Cobham to new premises in central London, and the Board has approved that from 12 June 2017 the new registered address will be Hamilton House, Mabledon Place, London, WC1H 9BB.

 

This office relocation marks the final step in the consolidation of company premises which also saw the integration of all laboratory capabilities in Frankfurt from 1 May 2017.

 

 

 

 

 

 

 

For further information:

 

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)1932 865065

Dr Ian Pike, Chief Scientific Officer

 

Geoff Ellis, Finance Director

 

finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson

 

 

Tel: +44 (0)20 7220 0500

Tony Quirke (broking)

 

IFC Advisory (Financial PR and IR)

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3053 8671

 

 

Notes for editors:

 

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

 

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

 

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAPKNEEFXEEF
Date   Source Headline
1st Jun 20267:00 amRNSDirectorate Changes
14th May 202612:55 pmRNSResult of AGM
14th May 202612:00 pmRNSAnnual General Meeting Statement
15th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
4th Feb 202611:08 amRNSHolding(s) in Company
3rd Feb 202612:43 pmRNSHolding(s) in Company
28th Jan 20263:31 pmRNSResult of Oversubscribed Retail Offer
26th Jan 20267:05 amRNSRetail Offer to raise up to £60,000
26th Jan 20267:00 amRNS£840,000 Fundraise and Retail Offer
6th Jan 20267:00 amRNSTwo Further Substantial Contracts for PRM
8th Dec 20257:00 amRNSSubstantial contract for Proteome Sciences
25th Nov 20257:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20257:00 amRNSInterim Results
16th May 20251:17 pmRNSResult of AGM
16th May 202512:00 pmRNSAGM Statement
10th Apr 20257:00 amRNSFinal Results
4th Apr 20251:00 pmRNSNotice of Results and Investor Presentation
21st Feb 20257:00 amRNSContract Win
23rd Dec 20247:08 amRNSLoan Facility, Trading Update & Directorate Change
13th Sep 20247:00 amRNSInterim Results and Directorate Change
16th May 20241:10 pmRNSResult of AGM
16th May 20247:00 amRNSAGM Statement
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.